[CAS NO. 518-47-8] Fluorescein sodium
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [518-47-8]
Catalog
HY-D0208
Brand
MCE
CAS
518-47-8
DESCRIPTION [518-47-8]
Overview
| MDL | MFCD00167039 |
|---|---|
| Molecular Weight | 376.27 |
| Molecular Formula | C20H10Na2O5 |
| SMILES | O=C1OC2(C3=C(OC4=C2C=CC(O[Na])=C4)C=C(O[Na])C=C3)C5=C1C=CC=C5 |
For research use only. We do not sell to patients.
Summary
Fluorescein (Uranine) sodium is widely used as a fluorescent tracer in medicinal and biological applications and tumor infected tissues tracer. Fluorescein (Uranine) sodium is a representative green fluorophore that has been widely used as a scaffold of practically useful green fluorescent probes [1] [2] .
In Vitro
Fluorescein is a synthetic organic photoactive dye compound soluble in water, alcohol and polar solvents [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02519920 | Shandong University |
Image Quality|Skin Discoloration
|
April 2015 | Phase 2 |
| NCT02389530 | University of Pittsburgh |
Brain Neoplasms
|
May 2015 | |
| NCT02717026 | Medical University of Graz |
Retinal Blood Vessels|Age-Related Macular Degeneration
|
July 2015 | |
| NCT01614184 | University of Utah |
Breast Cancer
|
May 2008 | Phase 1|Phase 2 |
| NCT03202173 | Eye & ENT Hospital of Fudan University |
Nasopharyngeal Carcinoma|Squamous Cell Carcinoma of the Head and Neck
|
January 1, 2017 | Not Applicable |
| NCT03303963 | Dissou AFFOLABI|Rwanda Biomedical Centre|The Tuberculosis Reference Laboratory Bamenda|Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo|Jimma University|Service de Pneumophtisiologie, Hôpital Ignace Deen|University of the Sciences, Techniques and Technologies of Bamako|Damien Foundation|Cheikh Anta Diop University, Senegal|Institute of Tropical Medicine, Belgium|World Health Organization|London School of Hygiene and Tropical Medicine|Genoscreen|Laboratoire de Référence des Mycobactéries |
Tuberculosis, Multidrug-Resistant
|
May 4, 2017 | |
| NCT01979003 | University of Arkansas |
Endometrial Cancer
|
September 2014 | Early Phase 1 |
| NCT03838679 | Medical University of Vienna |
Age-related Macular Degeneration|Choroidal Neovascularization
|
May 1, 2019 | |
| NCT05556525 | Mayo Clinic|National Cancer Institute (NCI) |
Lung Carcinoma
|
November 1, 2022 | Not Applicable |
| NCT03220711 | University of Michigan |
Colonic Dysplasia|Adenomatous Polyps|Irritable Bowel Disease
|
July 28, 2017 | Not Applicable |
| NCT03863171 | Beijing Friendship Hospital |
Ocular Ischemia Syndrome
|
March 1, 2019 | |
| NCT02534818 | Shandong University |
Gastric Intestinal Metaplasia
|
June 2015 | Phase 4 |
| NCT02476448 | Cecilia Calvo|The Cleveland Clinic |
Injury of Ureter
|
February 2015 | Not Applicable |
| NCT03297489 | Roswell Park Cancer Institute |
Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma|Stage I Ovarian Cancer|Stage IA Ovarian Cancer|Stage IB Ovarian Cancer|Stage IC Ovarian Cancer|Stage II Ovarian Cancer|Stage IIA Ovarian Cancer|Stage IIB Ovarian Cancer|Stage IIC Ovarian Cancer|Stage III Ovarian Cancer|Stage IIIA Ovarian Cancer|Stage IIIB Ovarian Cancer|Stage IIIC Ovarian Cancer|Stage IV Ovarian Cancer
|
November 6, 2017 | Early Phase 1 |
| NCT05105620 | Assiut University |
Eye Diseases|Diabetic Retinopathy
|
August 1, 2018 | |
| NCT02628496 | Washington University School of Medicine |
Laryngeal Dysplasia|Laryngeal Neoplasm
|
April 2015 | Not Applicable |
| NCT03244982 | Kresge Eye Institute |
Fluorescein Angiography
|
April 5, 2018 | Phase 4 |
| NCT02691923 | David W. Roberts|National Institute of Neurological Disorders and Stroke (NINDS)|Carl Zeiss Meditec, Inc.|Dartmouth-Hitchcock Medical Center |
Brain Cancer
|
March 2016 | Phase 2 |
| NCT03752203 | University of Colorado, Denver |
Pediatric Neurosurgical Tumors
|
August 11, 2021 | Not Applicable |
| NCT03279939 | Heidelberg Engineering GmbH |
Retinal Vascular|Normal Eyes
|
August 23, 2017 | Not Applicable |
| NCT04071080 | UpTru Inc.|Medicor Research Inc. |
Urine Sample Authenticity
|
August 22, 2019 | Phase 1 |
| NCT01959243 | Bausch & Lomb Incorporated|ORA, Inc. |
Hyperemia
|
February 22, 2014 | Phase 3 |
| NCT02677623 | Columbia University |
Ureteral Patency
|
March 2015 | Phase 4 |
| NCT01165697 | Ohio State University|Genzyme, a Sanofi Company |
Fabry Disease
|
July 2010 | |
| NCT02547909 | Dr. Ofir Harnoy MD|Sheba Medical Center |
Bowel Endometriosis
|
May 2016 | Not Applicable |
| NCT04008121 | MediBeacon |
Retinopathy|Retinal Vein Occlusion|Diabetic Retinopathy|Macular Degeneration
|
October 2022 | Early Phase 1 |
| NCT02757417 | University Hospitals Cleveland Medical Center|Megan Billow|Graham Chapman|Sangeeta Mahajan|Alex Soriano|Sherif El-Nashar |
Ureteral Injury
|
July 2016 | Not Applicable |
| NCT01384695 | Anandasabapathy, Sharmila, M.D. |
GERD|Barrett´s Esophagus
|
June 2009 | Early Phase 1 |
| NCT02857374 | Roswell Park Cancer Institute |
Stage IB Skin Melanoma|Stage IIA Skin Melanoma|Stage IIB Skin Melanoma|Stage IIC Skin Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma
|
November 3, 2016 | Not Applicable |
| NCT02478346 | AdventHealth |
Cerebrovascular Disorders|Intracranial Neoplasms
|
May 2015 | Phase 4 |
| NCT02552004 | IHU Strasbourg |
All Surgical Conditions Usually Necessitating Frozen Section|Malignant Tumor|Inflammatory Disease|Benign Tumor
|
October 13, 2015 | Not Applicable |
| NCT04140448 | Renmin Hospital of Wuhan University |
Retinal Vein Occlusion|Macular Edema
|
November 1, 2019 | |
| NCT03658551 | Johannes Gutenberg University Mainz |
Cirrhosis, Liver
|
August 1, 2017 | |
| NCT02540135 | University of Colorado, Denver |
High Grade Malignant Neoplasm|Glioblastoma Multiforme|Anaplastic Astrocytoma
|
March 1, 2015 | Not Applicable |
| NCT01886235 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Recurrent Melanoma|Stage IA Skin Melanoma|Stage IB Skin Melanoma|Stage IIA Skin Melanoma|Stage IIB Skin Melanoma|Stage IIC Skin Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma
|
September 4, 2013 | Not Applicable |
| NCT02703558 | Johns Hopkins University |
Intraoperative Cystoscopy
|
March 2016 | Not Applicable |
| NCT01034670 | Stanford University|National Institutes of Health (NIH) |
Gastrointestinal Diseases|Gastric (Stomach) Cancer|Gastrointestinal Stromal Tumor (GIST)
|
June 2009 | Not Applicable |
| NCT04351373 | Mayo Clinic |
Vestibular Schwannoma
|
October 6, 2021 | Phase 2 |
| NCT00847522 | University of Utah |
Cancer
|
February 2009 | Phase 1|Phase 2 |
| NCT02971800 | CHU de Quebec-Universite Laval |
Ureteral Injury
|
August 2016 | Not Applicable |
| NCT02843438 | University Hospital, Grenoble |
Subjects Clinically Suspected an Active Source of Toxoplasmosis Chorioretinitis Infection
|
January 2010 | Not Applicable |
| NCT02028325 | Indiana University|Sentara Norfolk General Hospital |
Adult Intracranial Neoplasm|Vascular: Intracranial
|
December 2013 | Phase 4 |
| NCT01959230 | Bausch & Lomb Incorporated|ORA, Inc. |
Hyperemia
|
November 7, 2013 | Phase 3 |
| NCT04687488 | Universitaire Ziekenhuizen KU Leuven |
Aerosol Generation and Droplet Dispersion and Deposition During Naso-gastric Intubation for Gastrointestinal Motility Investigations
|
July 23, 2020 | Not Applicable |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
In Vitro:
H 2 O : 20.83 mg/mL ( 55.36 mM ; ultrasonic and warming and heat to 80°C)
Preparing
Stock Solutions
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.6577 mL | 13.2883 mL | 26.5767 mL |
| 5 mM | 0.5315 mL | 2.6577 mL | 5.3153 mL |
| 10 mM | 0.2658 mL | 1.3288 mL | 2.6577 mL |
*
Please refer to the solubility information to select the appropriate solvent.
References
- [1] Hirabayashi K, et al. Analysis of chemical equilibrium of silicon-substituted fluorescein and its application to develop a scaffold for red fluorescent probes. Anal Chem. 2015;87(17):9061-9069.
- [2] Negm NA, et al. Fluorescein dye derivatives and their nanohybrids: Synthesis, characterization and antimicrobial activity. J Photochem Photobiol B. 2016;162:421-433.
Synonyms
Spiro[isobenzofuran-1(3H),9′-[9H]xanthen]-3-one, 3′,6′-dihydroxy-, sodium salt (1:2)
Fluorescein, disodium salt
Spiro[isobenzofuran-1(3H),9′-[9H]xanthen]-3-one, 3′,6′-dihydroxy-, disodium salt
Fluorin
Aizen Uranine
Calcocid Uranine B 4315
Certiqual Fluoresceine
C.I. Acid Yellow 73
Fluorescein sodium
Fluorescein Sodium B.P
Furanium
Hidacid Uranine
Resorcinol phthalein sodium
Sodium fluorescein
Sodium fluoresceinate
Soluble Fluorescein
Soluble Fluoresceine BPS
Uranin
Uranine
Uranine A extra
Uranine SS
Uranine WSS
Uranine O
11824 Yellow
12417 Yellow
C.I. 45350
D and C Yellow No. 8
Fluorescein sodium salt
Fluorescein disodium
Disodium fluorescein
Uranin S
3058 Uranine
Fluo-rectal
Fluorescite
Fluor-I-Strip
Ful-Glo
Obiturine
Uranine A
Japan Yellow 202(1)
Acid Yellow 73
Uranin A
Basacid Yellow 226
Fluorescein LT
Flurenate
D & C Yellow 8
Uranin Conc
D&C Yellow No. 8
5(6)-Carboxyfluorescein sodium
Fluoresceine DTD 842
Victacid Uranine
Urane U 307027
Fluoresein
Basovit Yellow 227
Simacid Fluoresceine Sodium
Sicomet Uranine S 45350
Fluoresceine Extra 019187
Simacid Fluoresceine LT
Dinacid Florescence Uranine
Cogilor Yellow 111.10
D&C Yellow No. 8-307225
Victacid Uranine VDC
Neelicol Fluorescein
Triacid Fluoresceine
Abbey Uranine
Dinacid Florescinece Uranine
ABCO Uranine
Sicomet Uranin S 45350
Neelicol Uranine
Uranine SSO
Yellow No. 202-1
Yellow 202-1
Fluorescein, soluble
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.